Arvind Manoharan1, William J Anderson, Joseph Lipworth, Brian J Lipworth. 1. Scottish Centre for Respiratory Research, Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, DD1 9SY, UK.
Abstract
INTRODUCTION: Guidelines advocate the use of spirometry to assess pulmonary function in asthmatic patients. Commonly used measures include forced expiratory volume in 1 s (FEV1), forced expiratory ratio (FEV1/FVC), and forced mid-expiratory flow between 25 and 75 % of forced vital capacity (FEF25-75). Impulse oscillometry (IOS) is an effort-independent test performed during tidal breathing. IOS may be used to assess the total and central airway resistance at 5 Hz (R5) and 20 Hz (R20), respectively, and hence derive the peripheral airway resistance from the difference (R5-R20). We compared spirometry and IOS as tests of global airway function (i.e., FEV1, FEV1/FVC, R5) and putative measures of small airways function (i.e., FEF25-75, R5-R20) and their relationship to oral steroid and short-acting beta-agonist (SABA) use as surrogates for long-term asthma control. METHODS: Spirometry and IOS measurements from physician-diagnosed asthmatics were linked to a health informatics database for oral steroid and SABA use 1 year prior to the index measurements. RESULTS: Four hundred forty-two patients had both spirometry and IOS, mean FEV1 = 86 % predicted, 94 % on ICS, median dose 800 µg/day. IOS and spirometry measures were equally predictive of impaired asthma control for both oral steroid and SABA use. For oral steroid use, the adjusted odds ratio, OR (95 % CI) is as follows: FEV1 < 80 %: 1.56(0.99-2.47), p = 0.056; FEV1/FVC < 0.70: 1.67(1.03-2.69), p = 0.037; FEF25-75 < 60 %: 1.84(1.18-2.86), p = 0.007; R5 > 150 %: 1.91(1.25-2.95), p = 0.003; and R5-R20 > 0.1 kPa L(-1) s 1.73(1.12-2.66), p = 0.013. For SABA use, the adjusted OR (95 % CI) is as follows: FEV1 < 80 %: 2.22(1.43-3.44), p < 0.001; FEV1/FVC < 0.70: 2.26(1.44-3.57), p < 0.001; FEF25-75 < 60 %: 2.51(1.65-3.82), p < 0.001; R5 > 150 %: 1.76(1.18-2.63), p = 0.006; and R5-R20 > 0.1 kPa L(-1) s: 2.94(1.94-4.46), p < 0.001. CONCLUSION: Spirometry or IOS measurements were equally useful as potential markers of asthma control in persistent asthmatic patients.
INTRODUCTION: Guidelines advocate the use of spirometry to assess pulmonary function in asthmatic patients. Commonly used measures include forced expiratory volume in 1 s (FEV1), forced expiratory ratio (FEV1/FVC), and forced mid-expiratory flow between 25 and 75 % of forced vital capacity (FEF25-75). Impulse oscillometry (IOS) is an effort-independent test performed during tidal breathing. IOS may be used to assess the total and central airway resistance at 5 Hz (R5) and 20 Hz (R20), respectively, and hence derive the peripheral airway resistance from the difference (R5-R20). We compared spirometry and IOS as tests of global airway function (i.e., FEV1, FEV1/FVC, R5) and putative measures of small airways function (i.e., FEF25-75, R5-R20) and their relationship to oral steroid and short-acting beta-agonist (SABA) use as surrogates for long-term asthma control. METHODS: Spirometry and IOS measurements from physician-diagnosed asthmatics were linked to a health informatics database for oral steroid and SABA use 1 year prior to the index measurements. RESULTS: Four hundred forty-two patients had both spirometry and IOS, mean FEV1 = 86 % predicted, 94 % on ICS, median dose 800 µg/day. IOS and spirometry measures were equally predictive of impaired asthma control for both oral steroid and SABA use. For oral steroid use, the adjusted odds ratio, OR (95 % CI) is as follows: FEV1 < 80 %: 1.56(0.99-2.47), p = 0.056; FEV1/FVC < 0.70: 1.67(1.03-2.69), p = 0.037; FEF25-75 < 60 %: 1.84(1.18-2.86), p = 0.007; R5 > 150 %: 1.91(1.25-2.95), p = 0.003; and R5-R20 > 0.1 kPa L(-1) s 1.73(1.12-2.66), p = 0.013. For SABA use, the adjusted OR (95 % CI) is as follows: FEV1 < 80 %: 2.22(1.43-3.44), p < 0.001; FEV1/FVC < 0.70: 2.26(1.44-3.57), p < 0.001; FEF25-75 < 60 %: 2.51(1.65-3.82), p < 0.001; R5 > 150 %: 1.76(1.18-2.63), p = 0.006; and R5-R20 > 0.1 kPa L(-1) s: 2.94(1.94-4.46), p < 0.001. CONCLUSION: Spirometry or IOS measurements were equally useful as potential markers of asthma control in persistent asthmatic patients.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: N Barnes; D Price; G Colice; A Chisholm; P Dorinsky; E V Hillyer; A Burden; A J Lee; R J Martin; N Roche; J von Ziegenweidt; E Israel Journal: Clin Exp Allergy Date: 2011-07-14 Impact factor: 5.018
Authors: David Price; Richard J Martin; Neil Barnes; Paul Dorinsky; Elliot Israel; Nicolas Roche; Alison Chisholm; Elizabeth V Hillyer; Linda Kemp; Amanda J Lee; Julie von Ziegenweidt; Gene Colice Journal: J Allergy Clin Immunol Date: 2010-08-09 Impact factor: 10.793
Authors: E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar Journal: Eur Respir J Date: 2008-01 Impact factor: 16.671
Authors: Devika R Rao; Jonathan M Gaffin; Sachin N Baxi; William J Sheehan; Elaine B Hoffman; Wanda Phipatanakul Journal: J Asthma Date: 2012-06-28 Impact factor: 2.515
Authors: S Gonem; S Natarajan; D Desai; S Corkill; A Singapuri; P Bradding; P Gustafsson; R Costanza; R Kajekar; H Parmar; C E Brightling; S Siddiqui Journal: Clin Exp Allergy Date: 2014-04 Impact factor: 5.018
Authors: Elizabeth F Juniper; David B Price; Patti A Stampone; Jacques P H M Creemers; Stijn J M Mol; Philip Fireman Journal: Chest Date: 2002-06 Impact factor: 9.410
Authors: Anthony Szema; Niely Mirsaidi; Bhumika Patel; Laura Viens; Edward Forsyth; Jonathan Li; Sophia Dang; Brittany Dukes; Jheison Giraldo; Preston Kim; Matthew Burns Journal: Am J Mens Health Date: 2015-12-14
Authors: Marcello Cottini; Carlo Lombardi; Giovanni Passalacqua; Diego Bagnasco; Alvise Berti; Pasquale Comberiati; Gianluca Imeri; Massimo Landi; Enrico Heffler Journal: Front Med (Lausanne) Date: 2022-05-23